Durability of Response to SARS-CoV-2 BNT162b2 Vaccination in Patients on Active Anticancer Treatment

Noa Eliakim-Raz; Amir Massarweh; Amos Stemmer; Salomon M Stemmer

doi:10.1001/jamaoncol.2021.4390

Durability of Response to SARS-CoV-2 BNT162b2 Vaccination in Patients on Active Anticancer Treatment

JAMA Oncol. 2021 Nov 1;7(11):1716-1718. doi: 10.1001/jamaoncol.2021.4390.

Authors

Noa Eliakim-Raz^{1

2

3}, Amir Massarweh⁴, Amos Stemmer⁵, Salomon M Stemmer^{3

4}

Affiliations

¹ Department of Medicine E, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel.
² Infectious Diseases Unit, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel.
³ Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
⁴ Davidoff Center, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel.
⁵ Department of Oncology, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.

Abstract

This cohort study examines the durability of immune response from BNT162b2 vaccination for severe acute respiratory syndrome coronavirus 2 in patients with cancer vs healthy controls.

Publication types

Comment

MeSH terms

BNT162 Vaccine
COVID-19 Vaccines
COVID-19*
Humans
SARS-CoV-2*
Vaccination

Substances

COVID-19 Vaccines
BNT162 Vaccine